Testosterone therapy and prostate cancer risk Multiple surveys of patient-reported outcomes from the phase 3 EMBARK trial revealed no meaningful differences in pain progression or urinary symptoms and ...
A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results